The funding will support the British Columbia Cancer Agency's effort to use genome sequencing to develop personalized treatment strategies for cancer patients.
Among 100 adults and six children recruited between June 2012 and August 2014, most were successfully sequenced and a majority of those had actionable results.
Researchers leading the POG trial are hoping this year to sequence the whole genomes of 300 cancer patients in an effort to find the best treatment options for them.
The goal is to analyze a variety of genomic techniques, including sequencing, to develop a test that will determine whether AML patients should receive chemotherapy or stem cell transplantation.
The Genome British Columbia program will kick off with funding totaling around $9 million for three personalized medicine studies.
In Science this week: convergent evolution in bird hemoglobin, and more.
The Wall Street Journal speaks with patients affected by questionable test results from Theranos.
Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.
Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.